#Remicade Biosimilars Scope

[colitisconfessions]

Short but kinda long update;

After being in remission with Remicade until 2020, I’ve been on Stelara (we thought was working but then immediately wasn’t), then switched to Humira biosimilar called Amgevita which never worked, but last scope in January of 2022 didn’t show enough inflammation to warrant a medication change. Tuesday I had a flexi-sig that showed significant inflammation so we are now in the process of starting Entyvio. I am really hoping and praying that this is it - I miss what life was like on Remicade, until I broke through. I don’t even know what I’ll do if life is like that again. I’ve just been flaring or on prednisone for the last three years.

I know everyone is so different, but if anyone has any advice, tips, tricks etc regarding Entyvio I would appreciate it - but please be gentle with me I’m not really in a place to accept failure stories right now.

[delicatemagazinedreamer]

Essential Things You Need to Know Remicade Biosimilars

A biosimilar is a category of biological product that is very similar to a medicine that has already received FDA approval, also referred to as a reference biological product. The U.S. FDA and the European Medicines Agency (EMA) both licence Remicade Biosimilars Market, which are identical to reference pharmaceuticals in terms of safety, purity, efficacy, and effectiveness.

Read more @ https://digitalgrowinfo.blogspot.com/2022/08/things-you-may-not-know-about-remicade.html

[sandlerresearch]

Digital Landscape: Ankylosing Spondylitis published on

http://www.sandlerresearch.org/digital-landscape-ankylosing-spondylitis.html

Digital Landscape: Ankylosing Spondylitis

Digital Landscape: Ankylosing Spondylitis

Summary

The “Digital Landscape: Ankylosing Spondylitis”, report analyzes digital activities undertaken by pharma in support of therapies for active Ankylosing Spondylitis (AS)

Key Highlights

– US Patients: AbbVie and Novartis provide the strongest online support to AS patients in the US. Novartis was the most active in 2017 with a new Cosentyx campaign and unbranded activity on social media, while Janssen launched a counter-biosimilar campaign for Remicade. No AS-specific mobile apps detected for patients from pharma. Opportunity exists for a well-integrated unbranded campaign to support patients, linked to social media and a mobile app. – US HCPs: Feature-rich HCP brand sites exist for all biologics. Amgen, Novartis, and Janssen added new AS content to existing sites in 2017, while AbbVie rolled out new Humira initiatives for HCPs. Unbranded and mobile app landscapes are sparse. Opportunities may exist to develop or sponsor content with trusted non-pharma organizations. Social media activity restricted to corporate accounts. – EUCAN Patients: AbbVie provides the strongest branded and unbranded support to EUCAN patients followed by Novartis. Most recent social media activity detected by Novartis, while UCB provides the only AS-specific mobile app. Opportunity exists to provide multi-country, local-language support, incorporating unbranded campaigns with social media and mobile apps, where regulations allow. – EUCAN HCPs: The EUCAN HCP landscape in AS is sparse; activity is mainly limited to brand sites, with most seen in Germany and the UK. The unbranded and mobile app landscapes are particularly underdeveloped, and partnerships with non-pharma organizations may offer more effective opportunities to engage with and support HCPs.

Scope

– This report analyzes digital activities undertaken by pharma in support of therapies for for active Ankylosing Spondylitis (AS). – The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps. – The report is based on analysis conducted by a combination of GlobalData’s digital and disease-specific teams. It also includes analysis of data licensed from third parties e.g. website traffic, search engine optimization (SEO), digital display advertising, mobile app downloads, and social media interaction. – The geographic scope of the report is the United States, Canada and the 5EU (UK, Germany, France, Italy & Spain), with EUCAN used as an abbreviation for Europe and Canada throughout. – This report covers the research period from January 2017 – December 2017.

Reasons to buy

– Our Digital Landscape report provides an analysis of pharma multichannel activity in the digital AS space, and can assist our pharma clients derive value in a number of ways. – Competitive Intelligence: Track and compare key competitor activity across channels and identify key trends in AS – Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns – Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands – Business Development & Licensing: Assess topics and trends shaping digital health in AS and beyond, and learn about key patient and physician online activities in AS.

[marketresearchtrendsblog]

Monoclonal Antibodies Market: Revenue Growth, Key Players, Qualitative Analysis, Forecast 2020-2028

The monoclonal antibody market is estimated to represent a global market of USD 135.6 billion by 2025 with growth rate of 4.8%. Biologics industry has been constantly on rise which strongly support the growth of monoclonal antibody market. Due to this fact, the utilization of monoclonal antibody has increased over the past few years owing to the increased awareness of these therapeutics among physicians and patients.For example, in 2012, approximately 20% of the total pharmaceutical revenue generated from biologic products and is anticipated to increase around 25% by the end of 2018. Furthermore, successful commercialization of monoclonal antibodies like Avastin, Rituxan and Remicade further boosted the customer base. For example, mAbs such as Avastin clocked more than US$ 6 billion of sale across the globe in 2013. Increasing uptake of these therapeutics support the market development. The market covers the analysis of the commercial or pipeline monoclonal antibody therapeutics such as Humira (adalimumab, anti-TNF), Enbrel, Remicade, Rituxan, Avastin, Herceptin, Lucentis, Erbitux, Eylea and many others.The global market is categorized in terms of source, end use and diseases. Based on source, the market is divided in murine, chimeric, humanized and human. Humanized and human segments are accounted for the largest share of the global market. Reason behind the high growth of this segments as these are considered as a natural drug and offers good safety on in vivo use.Synagis, Herceptin, Zenapax, Myelotarg, Campath, Xolair, Raptiva, Avastin, Tsyabri, Humira, Vectibix , and Cosentyx are some of the examples of human or humanized monoclonal antibodies. In terms of diseases, the market is segmented as autoimmune diseases, Inflammatory diseases, Infectious diseases and others. The utilization of monoclonal antibody therapeutics in cancer treatments and autoimmune diseases is whooping the market growth. Continuous rise in the incidence rate of cancer and autoimmune diseases along with growing demand for effective therapeutics in these area drive the market growth to great extent. End user segment is divided as hospitals, research laboratories and others. Hospitals segment dominated the market, captured almost 41.23% share of the global market in 2016.

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-53378 Regionally, developed regions such as North America and Europe are considered to be the largest market. Of which, North America accounted for almost 50% share of the global market in 2016. Increasing number of research and development activities coupled with rise in awareness among end users about monoclonal antibody drives the market growth. U.S. based Pfizer, Inc. is currently researching on avelumab—monoclonal antibody for indications such as non-small cell lung cancer, ovarian cancer, and others. These companies spenda significant share of their revenue on research activities, to develop novel mAbs. Europe is also considered to capture significant market share, 25% global share in 2016. Increasing approval of novel monoclonal antibodies is expected to stimulate the market demand. In 2012, European Medicines Agency (EMA) released guidelines on biosimilar mAb development. This guideline demonstrates the capability of biosimilar mAbs with an interest in development of similar biological mAbs, leading to drive market growth. Asia Pacific and Latin American countries are projected to grow with the promising growth rate during the future period. Companies such as F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc, Novartis AG; Pfizer; Shanghai Junshi Bioscience Co., Ltd, Daiichi Sankyo Company, Ltd., and others are operating in this market. These companies are engaged in strategic merger and acquisitions to expand their market share in this market. For example, Roche, Inc. acquired California based Genentech which has helped company to expand its market share in monoclonal antibody segment. Aside from Roche, Abbott Laboratories also exhibit strong potential in the monoclonal antibody sector. Growth of this company is attributed to its acquisition of Knoll Pharmaceutical Co. unit and licensing rights to MedImmune’s Synagis and Numax. Further, Johnson & Johnson enhance its market presence supported by the strong growth of Stelara (ustekinumab), Simponi (golimumab), and bapineuzumab. The market size and forecast for each segment has been provided for the period 2014 to 2025, considering 2015 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2016 to 2025 for every reported segment. The years considered for the study are: Historical Year – 2014 & 2015 Base Year – 2015 Estimated Year – 2016 Projected Year – 2025 TARGET AUDIENCE Traders, Distributors, And Suppliers Hospitals Manufacturers Government and Regional Agencies and Research Organizations Consultants Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows: MARKET, BY SOURCE Murine Chimeric Humanized Human MARKET, BY DISEASE Autoimmune diseases Inflammatory diseases Infectious diseases others MARKET, BY END USE Hospitals Research labs Others MARKET, BY REGION North America Europe Asia Pacific Rest of the World MARKET, BY COUNTRY Further Breakdown of The North America Market U.S. Canada Further Breakdown of The Europe Market Germany France Rest of Europe Further Breakdown of The APAC Market India China Rest of APAC Further Breakdown of The Rest of the World Market Middle-East and Africa Latin America

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

[reportsjournal]

Biosimilar of Remicade Market: Global Industry Analysis By Size, Share, Growth, Sourcing Strategy, Scope, Demand And Forecast To 2028

A new report on the Biosimilar of Remicade Market research study, published by Reports and Data, provides an in-depth survey of the dominant participants of the industry –the basis points for which are the financial highlights, company outline, SWOT Analysis, Product Portfolio, as well as major strategies and the expansion plans of the new and potential contenders. This report is also anticipated to reflect consistent growth in the coming years since consumers are now more aware of product quality. This market analysis of an industry is a crucial factor that numerous stakeholders, such as investors, traders, suppliers, and others, will find beneficial.

The research offered by the Biosimilar of Remicade report has been formulated through key analytical tools and extensive primary and secondary research further validated and verified by industry experts, industry professionals and analysts. The report includes SWOT analysis, Porter’s Five Forces analysis, feasibility analysis, and investment return analysis to impart better understanding of the Biosimilar of Remicade market dynamics. Key companies in the Biosimilar of Remicade market include: Janssen Biotech Inc., Merck &Co., Pfizer Inc. (AC. Hospira), Celltrion Inc., Alvogen, Napp Pharmaceuticals, and Nippon Kayaku are some major players in the global Remicade (infliximab  mAb) market.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/4029 For the purpose of this report, Reports and Data has segmented the Disposable Blood Pressure Cuffs market on the basis of Product Type, end use, and region:

Approved Indication Outlook (Revenue, USD Billion; 2018 – 2028)

Ulcerative Colitis

Rheumatoid Arthritis

Psoriatic Arthritis

Plaque Psoriasis

Crohn’s Disease

Ankylosing Spondylitis

Research findings and conclusion are offered through detail graphs, tables, charts, figures, and other pictorial representations. The report also includes a feasibility analysis and investment return analysis and aims to offer beneficial information that might help in formulating new business strategies and expansion plans. The report is a comprehensive overview of the industry, sales channel, distribution network, key strategies, growth prospects, drivers and restraints, and the key technological and product developments in the Biosimilar of Remicade market.

Ask for discount @ https://www.reportsanddata.com/discount-enquiry-form/4029 The report provides insights on the following pointers:

·         Market Penetration: Comprehensive information on the product portfolios of the top players in the Biosimilar of Remicade market.

·         Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

·         Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

·         Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

·         Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Biosimilar of Remicade market.

Key Questions Answered in this Research Study:

What     is the global production, production value and consumption value?

Who     are the global key manufacturers of the market? How are their operating     situation?

What     are the types and applications of market?

What     is the market share value of each type and application?

What     are the upstream raw materials and manufacturing equipment?

What     is the manufacturing process?

Economic     impact on the market and development trends of market.

What     will be the market size and the growth rate be in 2028?

What     are the key factors driving the market?

What     are the key market trends impacting the growth of the market?

What     are the challenges to market growth?

What     are the market opportunities and threats faced by the vendors in the     market?

To know more about the report @ https://www.reportsanddata.com/report-detail/biosimilar-of-remicade-market

Thank you for reading our report. For further inquiry, please get in touch with us. Our team will ensure the report is customized to meet your requirements.

[surajpalangemgi]

Global TNF Inhibitors Market 2020 By Covid-19 Impact Analysis, with Future Prospects, Trends, Growth, Key Player SWOT Analysis by 2026

Industry Insights:

The Global TNF Inhibitors market is anticipated to reach XX USD billion with CAGR of xx% over the forecast period 2020 - 2026.

‘Market Growth Insight’ has presented an updated research report on ‘The Global TNF Inhibitors market’ which offers insights on key aspects and an overview of the fundamental verticals of the market. The TNF Inhibitors report aims to educate buyers on the crucial impactful factors like drivers, challenges and opportunities for the market players, and risks. It comprises a thorough analysis of current TNF Inhibitors market trends as well as future trends. It also throws light on various quantitative and qualitative assessments of the market. The TNF Inhibitors research report covers every crucial aspect of the industry that impacts the existing market share, market size, profitability status, and more. A comprehensive evaluation on impacting factors the influence growth opportunities for TNF Inhibitors market players and remuneration.

Download your FREE sample of the report here: https://www.marketgrowthinsight.com/sample/145393

The Major Manufacturers Covered in This Report:

Janssen Biotech, Inc, Pfizer, AbbVie, Samsung Bioepis, UCB, Amgen, Johnson & Johnson, Takeda Pharmaceutical Company., Merck & Co, Novartis, Biogen

COVID-19 Outlook:

Researchers have extensively study on the impact of the pandemic on different segments of the TNF Inhibitors market. They have precisely mentioned the risks associated with the speedy spread of infection in different regions and offered insights on the crucial areas. This will help the businesses to plan their strategies for better TNF Inhibitors market position post-pandemic. The report also covers qualitative details about when the industry could return on track and potential measures adopted by the TNF Inhibitors market vendors to tackle the existing situation.

The report further elucidates on the restraining factors in the TNF Inhibitors market for business owners, strategists, and stakeholders to carefully execute their strategies and achieve their goals. In addition, the TNF Inhibitors market is segmented on the basis of product, technology, and end-user. These TNF Inhibitors report segments are thoroughly studied to offer key information like opportunities for business owners, planners, and marketing personnel. It helps them to manage their activities and execute decisive planning to earn more profits. TNF Inhibitors Report offers insights on each segment and sub-segment for assisting manufacturers to identify key opportunities and expand their business.

On the basis of the product, the market is categorized as:

Humira

Enbrel

Remicade

Simponi/Simponi Aria

Cimzia

Biosimilars

On the basis of end user, the market is sectioned as:

Rheumatoid Arthritis

Psoriasis

Psoriatic Arthritis

Crohn’s Disease

Ulcerative Colitis

Ankylosing Spondylitis

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa

Others

Geographically, the detailed analysis of consumption, revenue, TNF Inhibitors market share and growth rate, historic and forecast (2015-2026) of the following regions are covered:

North America (United States, Canada, Mexico) Europe (Germany, UK, France, Italy, Spain, Russia, Others) Asia-Pacific (China, Australia, South Korea, Japan, India, Southeast Asia, Others) Middle East and Africa (UAE, Saudi Arabia, Egypt, South Africa, Nigeria,  Others) South America (Brazil, Argentina, Columbia, Chile, Others)

Request a discount on standard prices of this premium research @ https://www.marketgrowthinsight.com/discount/145393

In addition, the report focuses on the key technological improvements in the products and key growth strategies adopted by TNF Inhibitors market players to expand their business vertically and horizontally. Company information, recent strategies, highly demanding products by manufacturers, and manufacturing units including other essential details are mentioned in the TNF Inhibitors study. Research and development activities and new product development and other trending factors are highlighted in the TNF Inhibitors report to offer deeper insights to the buyers. The TNF Inhibitors report is also beneficial to investors for their investment planning and company information.

Study Objective of the TNF Inhibitors market includes:

The key objective of the study is to evaluate global TNF Inhibitors market size (volume and value) by market players, major regions, product, application, and end-user, historical data, and predictions for 2026.

Also, other key objective is to determine market segments as well as sub-segments and to identify major factors that impact the TNF Inhibitors market growth like drivers, opportunities, growth potential, industry-specific challenges, and risks.

It also aims to forecast the volume and value of the TNF Inhibitors market in terms of key regions and countries.

To inspect and study the Global TNF Inhibitors Market size form the company, essential regions/countries, products and applications, background information and also predictions to 2026

Table and Figures Covered in This Report:

TNF Inhibitors Market Overview, Scope, Status, and Prospect

Global TNF Inhibitors Market Competition by Manufacturers

Global TNF Inhibitors Capacity, Production, Revenue (Value) by Region

Global TNF Inhibitors Supply (Production), Consumption, Export, Import by Region

Global TNF Inhibitors Production, Revenue (Value), Price Trend by Type

Global TNF Inhibitors Market Analysis by Application

Global TNF Inhibitors Manufacturers Profiles/Analysis

TNF Inhibitors Manufacturing Cost Analysis

Industrial Chain, Sourcing Strategy and Downstream Buyers

Marketing Strategy Analysis, Distributors/Traders

Market Effect Factors Analysis

Inquire more or share questions if any before the purchase on this report @ https://www.marketgrowthinsight.com/inquiry/145393

About Market Growth Insight

We are striving to provide the best customer friendly services and appropriate business information to accomplish your ideas. The skilled and experienced professionals at Market Growth Insight are our strength and the position we have earned in the industry. This is what makes us to offer our clients to excel and enable competitive prices while retaining the best services. We are incorporated with a vision to provide the complete solution required for successful business execution. Our only motto is to resolve customer fulfillment completely. We provide the quality and customized research reports from the best publishers in the world.

Contact Us:

Direct Line: +1 3477675477 (US) Email: sales@marketgrowthinsight.com Web: https://www.marketgrowthinsight.com

[kisan512posts]

Antibody Drugs -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024

Antibody Drugs Industry

Description

Wiseguyreports.Com Adds “Antibody Drugs -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database

Antibody drugs are created through the use of modern scientific techniques such as genetic engineering and recombinant deoxyribonucleic acid (DNA) technology. They are produced by living cells and organisms such as Escherichia coli (E. coli), yeast, mammalian cells, etc. These protein drugs have gained in significance due to the increase in the number of chronic diseases such as asthma, multiple sclerosis and arthritis, and fatal diseases such as cancer and cardiovascular diseases. The antibody drug industry has grown globally due to its pivotal role in the treatment of life-threatening diseases. This report analyzes and assesses the therapeutic applications of antibodies such as mAbs in human medicine, including the combination of mAbs when they are attached to cytotoxic agents, such as antibody drug conjugates.

Genetic engineering technology has made it possible to produce these protein molecules with modified features. Owing to its high specificity and low immunogenicity, protein therapeutics is widely used to treat various life-threatening diseases such as cancer, diabetes and multiple sclerosis. Increasing R&D, increasingly sedentary lifestyles, increasing incidence of various diseases and the growing population of baby-boomers are the driving forces for the monoclonal antibody market.

Leading manufacturers of mAbs include F. Hoffmann-La Roche Ltd., Johnson & Johnson Inc., Novartis AG, Biogen Inc., Amgen Inc., Merck KGaA, Seattle Genetics Inc. and AbbVie Inc. More and more novel antibody drugs are being investigated and developed due to advances in technology. Approaches such as the development of antibody drug conjugates and bi-specific antibodies that attack the proteins present inside a cancerous cell are the present-day outlook of R&D of therapies. These therapies suppress the further progression of diseases such as arthritis, multiple sclerosis, hepatitis, Crohn’s disease, acquired immunodeficiency syndrome (AIDS), etc.

The global antibody drug market is expected to be $114.6 billion by 2022 with a CAGR of 6.3%. Humanized monoclonal antibodies (mAbs) are the largest segment in terms of revenue, followed by other mAb categories such as human, chimeric and murine. The use of mAbs in therapeutics such as oncology, autoimmune and inflammatory diseases is expected to increase during the forecast period although this market is likely to face competition from the entry of follow-on-biologics and biosimilars.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3248874-antibody-drugs-technologies-and-global-markets

The market is radically changing as biosimilars come onto the market and the patents for many mAbs are expiring. The previous report forecast the market to be around $122.6 billion at a CAGR of 12.2% through 2019. The major decrease occurred in the European market due to the patent expiry of the blockbuster drug Remicade from Johnson & Johnson in 2015. The market witnessed the entry of biosimilars like Inflectra from Pfizer. This resulted in dropping the CAGR for the forecast period to 6.3%. The European market is expected to slow down due to a higher acceptance rate of biosimilars by physicians as well as by patients (end users).

This report covers a new company Genmab A/S in the mAb manufacturing arena with its drug products Arzerra and Darzalex. One of the major changes that are observed in the current report is the slowdown in the market for murine mAbs. GlaxoSmithKline stopped production of its drug Bexxar in 2014. Despite the changes in the market scenario, it is expected to show a positive growth through the forecast period due to new approvals in the market and a robust pipeline among various manufacturers.

Report Scope:

This study offers a global view of the antibody drugs used in the pharmaceutical and biopharmaceutical markets. This report analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when they are attached to cytotoxic agents such as antibody drug conjugates.

BCC Research analyzes and makes projections for each market and its applications, the regulatory environment, new products and technological advances. Also included in the report are relevant patent analysis and profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Biogen Inc., Johnson & Johnson Inc., Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd. and Merck & Co.

The report covers the major markets of the U.S. and Europe, as well as emerging markets in India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, etc.

Monoclonal antibodies are protein-based therapies/drugs that are finding use in the treatment of number of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review on their applications in various disease sectors. The overall market for antibody drug products includes four main areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.

The report covers technology trends, including the human anti-mouse antibody (HAMA) problem caused by murine antibodies and how it was resolved by replacing murine antibodies with chimeric, human and humanized antibodies.

Excluded from this report are polyclonal antibodies; screening kits; and diagnostic uses of mAbs. Also excluded are research applications of mAbs and therapeutic antibodies for veterinary use.

Leave a Query @ https://www.wiseguyreports.com/enquiry/3248874-antibody-drugs-technologies-and-global-markets

Report Includes:

– An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies. – Analyses of global market trends, with data from 2014, 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022. – Analysis and assessment of the therapeutic applications of mAbs in human medicine. – A look at the antibody industry as a whole, as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market. – Comprehensive profiles of companies that lead the biotechnology and pharmaceutical industries in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.

ABBVIE INC. ALEXION PHARMACEUTICALS INC AMGEN INC. ASTRAZENECA PLC. BIOGEN INC. BRISTOL-MYERS SQUIBB CO ELI LILLY AND CO. FRESENIUS KABI USA GENMAB A/S GILEAD INC. GLAXOSMITHKLINE F. HOFFMANN-LA ROCHE LTD. JOHNSON & JOHNSON INC. MERCK & CO. INC. MERCK KGAA NOVARTIS AG PFIZER INC. SANOFI INC. SEATTLE GENETICS INC. SPECTRUM PHARMACEUTICALS INC. TAKEDA PHARMACEUTICAL U.S.A., INC. UCB

Table of Contents

Chapter 1: Introduction …………………………………………………………………………….. 1 Chapter 2: Summary and Highlights …………………………………………………………….. 8 Chapter 3: Market and Technology Background …………………………………………. 11 Chapter 4: Market Breakdown by Technology Type …………………………………….. 24 Chapter 5: Market Breakdown by Application …………………………………………….. 49 Chapter 6: Industry Structure …………………………………………………………………… 73 Chapter 7: Regulatory Aspects ………………………………………………………………….. 81 Chapter 8: Patent Review/ New Developments …………………………………………… 86 Chapter 9: Analysis of Market Opportunities …………………………………………….. 103 Chapter 10: Company Profiles ………………………………………………………………… 108 Appendix: Abbreviations ………………………………………………………………………… 121 About BCC Research …………………………………………………………………………….. 123 About BCC Research…………………………………………………………………………………………………………………. 124 BCC Membership …………………………………………………………………………………………………………………….. 124 BCC Custom Research ………………………………………………………………………………………………………………. 124

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=3248874

Continued…                      

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us)  Ph: +44 208 133 9349 (Uk)

NOTE : Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

[megasddw-blog]

Generic Injectables Market Growth Drivers, Applications and Forecast to 2023

The Report of Global Generic Injectables Market by Market Research Future Covers the Information like Global Generic Injectables Market Growth, Prominent Players, Upcoming Trends, Business Analysis, chapter-wise Description followed by various user perceptions.

Market Highlights:

Global Generic Injectables Market is Expected to Register a CAGR ~13% during the forecast period of 2018–2023. Generic injectables is a key feedstock in pharmaceutical, diagnostics, biotechnology, diagnostic, and veterinary industries.

The Americas generic injectables market is expected to witness tremendous growth owing to the expansion of biosimilar products with off patenting of the major patented drugs is expected to drive growth of generic sterile injectable market during forecast period. For example, the loss of patent in 2017 for blockbuster brands such as Cancidas, Remicade, Cubicin, Invanz and Humira leading to entry of generic products. is also expected to drive the market. Other key factors such as the untapped market opportunities in emerging countries, growing investments by government organizations are contributing towards the growth of the market. However, in the negative perception of the consumers towards generic drugs coupled with stringent regulations laid down by the governments are few factors restraining the growth of the market.

Request Free Sample copy at https://www.marketresearchfuture.com/sample_request/7512

Key Players:

Some of the key players in the global generic injectables market are Novartis AG (Sandoz International GmbH), Baxter, Fresenius SE & Co. KGaA, Mylan N.V., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals plc, Lupin Ltd., Sanofi, Biocon, Dr. Reddy’s Laboratories, Aurobindo Pharma, Sagent Pharmaceuticals Inc., Zydus Cadila, GlaxoSmithKline plc, AstraZeneca plc., among others.

Segments:

The global generic injectable market is segmented on the basis of product type, container, application, and distribution channel.

Regional Analysis:

On the regional basis, the generic injectables market in the Americas is predicted to dominate the market during the forecast period. The North American region holds substantial share in the global market. Unlike branded drug manufacturers that invest huge amount of capital on R&D and marketing, generic drug manufacturers do not require such investments. Furthermore, the number of competitors in the generic injectables market is lower as compared to oral generics, resulting in limited price erosion and significantly higher profit margins.

Currently, the global generic injectables market is dominated by numerous players. The major players in this market are involved in new product launches, strategic partnerships and collaborations to increase their product portfolio. For instance, in December 2016, Baxter acquired injectables from Claris for the production of injectable medicines such as anesthesia and analgesics, anti-infective, renal, and critical care medications.

Some Points From TOC of Generic Injectables Market Research Report – Global Forecast till 2023:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Overview

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

Chapter 5. Market Factor Analysis

TOC CONTINUED…

Browse Complete 100 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at https://www.marketresearchfuture.com/reports/generic-injectables-market-7512

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

[sandlerresearch]

Crohn's Disease - Global Drug Forecast and Market Analysis to 2029 published on

https://www.sandlerresearch.org/crohns-disease-global-drug-forecast-and-market-analysis-to-2029.html

Crohn's Disease - Global Drug Forecast and Market Analysis to 2029

Crohn’s Disease – Global Drug Forecast and Market Analysis to 2029

Summary

Crohn’s disease (CD) is a form of inflammatory bowel disease (IBD), which is composed of two chronic autoimmune diseases that cause intestinal inflammation: Crohn’s disease (CD) and ulcerative colitis (UC). In CD, chronic inflammation may affect any part of the gastrointestinal (GI) tract from the mouth to the anal area; however, CD occurs most commonly in the lower part of the small intestine (ileum) and in the large intestine. The pathophysiology of CD is complex, as the disease is characterized by recurring flares that evolve along with periods of inactivity and remission. The CD market has historically been reliant on anti-tumor necrosis factor (anti-TNF) therapies that have been available for over a decade but recent developments have led to research on novel treatment mechanisms.

In May 2014, Takeda gained approval for Entyvio (vedolizumab), the first-in-class ?4?7 integrin inhibitor that was the first new biologic treatment approved for CD that was not an anti-TNF, and this was followed by Janssen’s Stelara (ustekinumab) in September 2016, which was a first-in-class interleukin (IL)-12 and 23 inhibitor. Moreover, biosimilars of currently marketed anti-TNF biologics recently entered the market, with Remicade (infliximab) biosimilars first marketed in 2015 in Europe and 2016 in the US, and adalimumab biosimilars first marketed in Europe in 2018. This is likely to result in a highly competitive market for patients who have failed first-line agents, such as steroids, aminosalicylates, and immunomodulators. Competition will intensify with the arrival of new anti-IL-23 treatments and new classes of therapies in development, Janus kinase (JAK) inhibitors and sphingosine-1-phosphate receptor (S1PR) modulators, which will offer a more convenient form of administration. With existing unmet need for all patients, particularly CD patients that experience loss of response to biologic treatment and patients that develop fistulizing disease, CD represents an important immunology sector for drug developers.

GlobalData estimates that sales of drugs in the CD market were approximately $7.4B in 2019 in the 8MM. The US was the largest market, with approximately $5.8B in drug sales, which represented 78.9% of the total CD market. The 5EU market contributed $1.3B in sales, Japan contributed sales of $133.2M, and Canada contributed sales of $148.9M in 2019. Global sales in the CD market are expected to grow to $12.6B by 2029, at a Compound Annual Growth Rate (CAGR) of 5.5% from 2019-2029. GlobalData forecasts the US CD market to grow to $10.4B (82.3% of global sales), the 5EU to grow to $1.9B (14.7% of global sales), Japan to grow to $174.9M (1.4% of global sales), and Canada to grow to $200.1M (1.6% of global sales) over the next 10 years.

Key Highlights

– The greatest driver of growth in the global CD market will be the launches of 11 pipeline therapies during the forecast period. The entry of these anticipated therapies, including AbbVie’s Skyrizi and Takeda’s subcutaneous Entyvio, will be subject to substantial uptake among moderate to severe CD patients. – The main barrier to growth in the CD market will be the patent expiry, and subsequent launch of biosimilars of Humira (adalimumab) in the US, and the launch of Entyvio and Stelara biosimilars across the 8MM. – The most important unmet needs in CD are the need for more efficacious and safe drugs and the inability to determine which treatment best suits each patient. The former is being addressed by the development of drugs with novel mechanisms of action, and the latter is being addressed by the discovery of new biomarkers. – The increasing diagnosed prevalence across the 8MM over the forecast period, rising from 0.16% in 2019 to 0.19% in 2029, which can be attributed to increased diagnosis in some markets, will lead to a greater CD patient pool eligible for treatment.

Key Questions Answered

– Over the forecast period, the CD market will see the entry of pipeline agents such as anti-IL-23 biologics, JAK inhibitors, and S1P receptor modulators, the sales of which will offset the loss of sales caused by the entry of biosimilars. How do products compete against each other? Which of these drugs will have the highest peak sales, and why? – Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are several unmet needs within the CD indication. What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs? – The CD market is likely to become a turbulent space throughout the forecast period and beyond. Which companies are set to be major players in CD during the forecast period?

Scope

– Overview of CD including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. – Annualized CD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2019 and forecast for ten years to 2029. – Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CD therapeutics market. – Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. – Analysis of the current and future market competition in the global CD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to – – Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global CD therapeutics market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CD therapeutics market in future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. – Track drug sales in the global CD therapeutics market from 2019-2029. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

[markhub123-blog]

Global Drug Forecast and Market Report to 2025- PharmaPoint: Psoriatic Arthritis

Albany, New York, February 24, 2017: Market Research Hub has recently announced the addition of a new report to it broad database titled as “PharmaPoint: Psoriatic Arthritis Global Drug Forecast and Market Analysis to 2025”. Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially those of the lower extremities and distal joints of the fingers and toes as well as the back and sacroiliac joints of the pelvis.

Request for Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=990986

Summary In approximately 80% of PsA patients, skin lesions of psoriasis (PsO), an immune-mediated skin disease, manifest prior to the development of PsA, typically by five to 10 years. PsA most commonly develops between the ages of 30 and 50 and affects men and women equally. Although, early diagnosis and intervention are key in preventing irreversible joint damage, many PsA patients are undiagnosed and go untreated for months or years. GlobalData projects the PsA market in 7MM to experience strong growth during the forecast period at a CAGR of 10.74%. By the forecast's end in 2025, sales will increase to over $12.58 billion from $4.53 billion in 2015. This growth will be driven primarily by the increase in diagnosed prevalent cases from 1,044,022 in 2015 to 1,520,471 in 2025. Further, the launch of the IL-17 inhibitors, including Novartis' Cosentyx, Eli Lilly's Taltz, and AstraZeneca's Lumicef, as well as the launch of Celgene's oral therapy Otezla, will expand the treatment armamentarium for PsA driving growth in the market. Highlights Key Questions Answered - How large an impact will biosimilars have on the PsA market? What do dermatologists, rheumatologists, and key opinion leaders across the 7MM think about the evolving treatment landscape? - What opportunities remain in the market for new product entrants? - What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the PsA market? - According to KOLs, what are the most important unmet needs in PsA? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2025? - What clinical and commercial factors are likely to affect uptake of PsA therapies in the US, 5EU, and Japan?

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=990986

Key Findings - The PsA market is currently very dynamic, with effective biologic therapies recently approved, including interleukin-17 (IL-17) inhibitors - Cosentyx, Taltz, and Lumicef - and oral phosphodiesterase-4 (PDE4) - Otezla. - Novel biologic therapies will challenge the current anti-TNF biologics in an attempt to dislodge their stronghold, if their safety and efficacy profiles are proven once they enter the market. - The impending patent cliff for biologics will allow for the emergence of biosimilars to all the marketed biologic brands. Patent expiries take place during the forecast period for the current market leaders such as Johnson & Johnsons Remicade (infliximab), AbbVies Humira (adalimumab), Amgens Enbrel (etanercept) and Johnson & Johnsons Stelara (ustekinumab). - The drivers for market growth will include the increasing diagnosis rate as well as the recent approval of novel therapies. The main challenge for individual drugs will be to distinguish themselves in a crowded marketplace, comprising a highly diversified field of therapies, with existing drugs struggling to increase their patient share. Scope - Overview of PsA, including epidemiology, etiology, pathophysiology, symptoms and country-specific diagnosis and treatment recommendations. - Annualized PsA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the PsA market. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of novel products- including promising IL-17 inhibitors - and biosimilars - such as Celltrions Hospira, Sandozs Erelzi, Biogen/Samsung Bioepies Flixabi and Benepali, and Amgens Amjevita. - Analysis of the current and future market competition in the global PsA market (7MM). Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Get Full Info. With TOC: http://www.marketresearchhub.com/report/pharmapoint-psoriatic-arthritis-global-drug-forecast-and-market-analysis-to-2025-report.html

Reasons to buy The report will enable you to -  - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Psoriasis market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Psoriasis market in the future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global PsA market from 2015-2025. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 866-997-4948 (US-Canada)

Tel: +1-518-621-2074

Email: press@marketresearchhub.com

Website: http://www.marketresearchhub.com/

Follow Us on: Twitter, LinkedIn, Facebook

Twitter: https://twitter.com/MktResearchHub

LinkedIn: https://www.linkedin.com/company/market-research-hub

Facebook: https://www.facebook.com/MarketResearchHub/

[healthy-insights]

Rheumatology Therapeutics Market Research Report Forecast To 2013 – 2019

With increasing joint and connective tissue problems caused by hectic lifestyles, non-nutritious food habits, and lack of physical workouts, the demand for rheumatology is on an increase on a global scale. Rheumatology is concerned with the therapy of rheumatic diseases and problems involving joints, soft tissues, autoimmune diseases, heritable connective tissue disorders, and vasculitis. Some of the major rheumatic conditions are neck pain, back pain, osteoarthritis, and bursitis. From 2005 to 2011, the rheumatology therapeutics market has grown at an encouraging rate, but during the period from 2012 to 2018, it is expected to grow at a slow pace. Some of the key drivers of the rheumatology therapeutics market are increasing population with joint problems, the improving technology in the medical field, increased research and development expenditure on healthcare, and the growing willingness of people to stay fit.

The market can be segmented on the basis of drugs used in rheumatology therapeutics into Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) Enbrel (etanercept). Humira (adalimumab) and Remicade (infliximab) are the major shareholders of the drugs used in rheumatology therapeutics, out of which Enbrel and Humira have the majority of the market share in the U.S. while Remicade holds its roots in the European Union. Pfizer’s Celebrex, a major drug used for the treatment of osteoarthritis, saw high sales during 2010-11 and is expected to be demanded more during the period from 2012 to 2016.

The market of rheumatology therapeutics suffers restraints due to the entry of biosimilars despite healthy sales and the positive impact of the expanding geriatric population. The entry of biosimilars will slow the growth of the rheumatology therapeutics market. During the period from 2012 to 2018, the annual growth rate of the rheumatology therapeutics market is expected to fall. The opportunities that the market has are a growing aging population which leads to an increase in the number of joint problems, a rise in the disposable income of individuals, and increased concerns regarding health.

Browse Global Strategic Business Report: http://www.transparencymarketresearch.com/rheumatology-therapeutics-market.html

Some of the market players in this industry are Abbott Laboratories, Pfizer, Janssen Biotech, Merck, Amgen and others.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

North America

Asia Pacific

Europe

Rest of the World

This report provides comprehensive analysis of

Market growth drivers

Factors limiting market growth

Current market trends

Market structure

Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a technological growth map over time to understand the industry growth rate

It provides a seven-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

It provides distinctive graphics and exemplified SWOT analysis of major market segments

Download Exclusive Brochure of This Report :

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1494

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

[sandlerresearch]

Axial Spondyloarthritis: Global Drug Forecast and Market Analysis to 2028 published on

http://www.sandlerresearch.org/axial-spondyloarthritis-global-drug-forecast-and-market-analysis-to-2028.html

Axial Spondyloarthritis: Global Drug Forecast and Market Analysis to 2028

Axial Spondyloarthritis: Global Drug Forecast and Market Analysis to 2028

Summary

Axial spondyloarthritis (axSpA) is a disease group encompassing both ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). These conditions are chronic, autoinflammatory disorders of the sacroiliac joints and spine, an area also known as the axial skeleton. The disease is typically diagnosed in young adulthood to middle age (16-45 years) and has a seven- to nine-year delay of diagnosis. The axSpA market has historically been reliant on anti-tumor necrosis factor (TNF) therapies that have been available for over a decade, and the pipeline for drugs in late-stage development was lacking, but recent developments have led to research on novel treatment mechanisms. This will be vital in treating the underdiagnosed nr-axSpA population.

In January 2016, Novartis gained approval for Cosentyx (secukinumab), the first-in-class interleukin (IL)-17 inhibitor that was the first new biologic treatment approved for AS that was not an anti-TNF. Moreover, biosimilars of currently marketed anti-TNF biologics recently entered the market, with Remicade (infliximab) biosimilars first marketed in 2015 in Europe. This is likely to result in a highly competitive market for patients who have failed multiple non-steroidal anti-inflammatory drugs (NSAIDs). Competition will intensify with the arrival of new anti-IL-17 treatments and a new class of therapies in development, Janus kinase (JAK) inhibitors, which will offer a more convenient form of administration. With existing unmet need for all patients, particularly nr-axSpA patients, being diagnosed in a timely manner and having treatment options that are not solely subcutaneously or intravenously administered, axSpA represents an increasingly important rheumatology sector for drug developers.

GlobalData estimates that sales of drugs in the axSpA market were approximately $3.1B in 2018 in the 7MM. The US was the largest market, with approximately $2.3B in drug sales, which represented 75.3% of the total axSpA market. The 5EU market contributed $705M in sales and Japan contributed sales of $54M in 2018.

Global sales in the axSpA market are expected to grow to $3.6B by 2028, at a Compound Annual Growth Rate (CAGR) of 1.5% from 2018-2028. GlobalData forecasts the US to grow to $2.7B (74.7% of global sales), the 5EU to grow to $850M (23.9% of global sales), and Japan to shrink to $52M (1.5% of global sales) over the next 10 years.

Key Questions Answered

Over the forecast period, the axSpA market will see the entry of pipeline agents such as the interleukin 17 inhibitors and the JAK inhibitors, the sales of which will offset the loss of sales caused by the entry of biosimilars. How do products compete against each other? Which of these drugs will have the highest peak sales, and why? Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are several unmet needs within the axSpA indication. What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs? The axSpA market is likely to become a turbulent space throughout the forecast period and beyond. Which companies are set to be major players in axSpA during the forecast period?

Key Highlights

The greatest driver of growth in the global axSpA market will be the launches of five pipeline therapies during the forecast period. The entry of these anticipated therapies, including Eli Lilly’s Taltz and Pfizer’s tofacitinib, will be subject to moderate uptake among the AS and nr-axSpA populations.

The main barrier to growth in the axSpA market will be the patent expiry, and subsequent launch of biosimilars of Humira (adalimumab) in the US, and the genericization of tofacitinib in the latter half of the forecast across the 7MM.

The most important unmet needs in axSpA are the need for speedier diagnosis and convincing patients to start biologic therapy. The former is being addressed by the increasingly routine use of MRI instead of X-ray to diagnose patients, and the greater understanding and awareness of nr-axSpA. The latter is impacted by poor patient education about their disease and a fear of subcutaneous/intravenous injection.

Factors driving a low biologic therapy treatment rate include some negative or fearful attitudes towards subcutaneously/intravenously administered therapeutics, nr-axSpA patients not perceiving themselves as severe enough to warrant biologic treatment, and a high ACOT for some biologic therapies currently on the market and in late-stage development.

Scope

– Overview of axSpA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. – Annualized axSpA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2018 and forecast for ten years to 2028. – Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the axSpA therapeutics market. – Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. – Analysis of the current and future market competition in the global axSpA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to – – Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global axSpA therapeutics market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global axSpA therapeutics market in future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. – Track drug sales in the global axSpA therapeutics market from 2018-2028. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

[megasddw-blog]

Generic Injectables Market – Currents Trends and Graphs Growth Factors in Healthcare

Global Generic Injectables Market Report Split Into Several Key Regions, With Sales, Revenue, And Market Share And Growth Rate. Covering North America, Europe, Asia Pacific, Middle East and Africa. And It Is Incorporated On Marketresearchfuture.Com With 100 Pages.

Global Generic Injectables Market is Expected to Register a CAGR ~13% during the forecast period of 2018–2023. Generic injectables is a key feedstock in pharmaceutical, diagnostics, biotechnology, diagnostic, and veterinary industries.

The Americas generic injectables market is expected to witness tremendous growth owing to the expansion of biosimilar products with off patenting of the major patented drugs is expected to drive growth of generic sterile injectable market during forecast period. For example, the loss of patent in 2017 for blockbuster brands such as Cancidas, Remicade, Cubicin, Invanz and Humira leading to entry of generic products. is also expected to drive the market. Other key factors such as the untapped market opportunities in emerging countries, growing investments by government organizations are contributing towards the growth of the market. However, in the negative perception of the consumers towards generic drugs coupled with stringent regulations laid down by the governments are few factors restraining the growth of the market.

Request Sample copy at https://www.marketresearchfuture.com/sample_request/7512

Key Players:

Some of the key players in the global generic injectables market are Novartis AG (Sandoz International GmbH), Baxter, Fresenius SE & Co. KGaA, Mylan N.V., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals plc, Lupin Ltd., Sanofi, Biocon, Dr. Reddy’s Laboratories, Aurobindo Pharma, Sagent Pharmaceuticals Inc., Zydus Cadila, GlaxoSmithKline plc, AstraZeneca plc., among others.

Segments:

The global generic injectable market is segmented on the basis of product type, container, application, and distribution channel.

Regional Analysis:

On the regional basis, the generic injectables market in the Americas is predicted to dominate the market during the forecast period. The North American region holds substantial share in the global market. Unlike branded drug manufacturers that invest huge amount of capital on R&D and marketing, generic drug manufacturers do not require such investments. Furthermore, the number of competitors in the generic injectables market is lower as compared to oral generics, resulting in limited price erosion and significantly higher profit margins.

Currently, the global generic injectables market is dominated by numerous players. The major players in this market are involved in new product launches, strategic partnerships and collaborations to increase their product portfolio. For instance, in December 2016, Baxter acquired injectables from Claris for the production of injectable medicines such as anesthesia and analgesics, anti-infective, renal, and critical care medications.

Some Points From TOC of Generic Injectables Market Research Report – Global Forecast till 2023:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Overview

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

Chapter 5. Market Factor Analysis

TOC CONTINUED…

Browse Complete 100 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at https://www.marketresearchfuture.com/reports/generic-injectables-market-7512

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

[megasddw-blog]

Generic Injectables Market – Currents Trends and Graphs Growth Factors in Healthcare

Global Generic Injectables Market Report Split Into Several Key Regions, With Sales, Revenue, And Market Share And Growth Rate. Covering North America, Europe, Asia Pacific, Middle East and Africa. And It Is Incorporated On Marketresearchfuture.Com With 100 Pages.

Market Highlights:

Global Generic Injectables Market is Expected to Register a CAGR ~13% during the forecast period of 2018–2023. Generic injectables is a key feedstock in pharmaceutical, diagnostics, biotechnology, diagnostic, and veterinary industries.

The Americas generic injectables market is expected to witness tremendous growth owing to the expansion of biosimilar products with off patenting of the major patented drugs is expected to drive growth of generic sterile injectable market during forecast period. For example, the loss of patent in 2017 for blockbuster brands such as Cancidas, Remicade, Cubicin, Invanz and Humira leading to entry of generic products. is also expected to drive the market. Other key factors such as the untapped market opportunities in emerging countries, growing investments by government organizations are contributing towards the growth of the market. However, in the negative perception of the consumers towards generic drugs coupled with stringent regulations laid down by the governments are few factors restraining the growth of the market.

Request Sample copy at https://www.marketresearchfuture.com/sample_request/7512

Key Players:

Some of the key players in the global generic injectables market are Novartis AG (Sandoz International GmbH), Baxter, Fresenius SE & Co. KGaA, Mylan N.V., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals plc, Lupin Ltd., Sanofi, Biocon, Dr. Reddy’s Laboratories, Aurobindo Pharma, Sagent Pharmaceuticals Inc., Zydus Cadila, GlaxoSmithKline plc, AstraZeneca plc., among others.

Segments:

The global generic injectable market is segmented on the basis of product type, container, application, and distribution channel.

Regional Analysis:

On the regional basis, the generic injectables market in the Americas is predicted to dominate the market during the forecast period. The North American region holds substantial share in the global market. Unlike branded drug manufacturers that invest huge amount of capital on R&D and marketing, generic drug manufacturers do not require such investments. Furthermore, the number of competitors in the generic injectables market is lower as compared to oral generics, resulting in limited price erosion and significantly higher profit margins.

Currently, the global generic injectables market is dominated by numerous players. The major players in this market are involved in new product launches, strategic partnerships and collaborations to increase their product portfolio. For instance, in December 2016, Baxter acquired injectables from Claris for the production of injectable medicines such as anesthesia and analgesics, anti-infective, renal, and critical care medications.

Some Points From TOC of Generic Injectables Market Research Report – Global Forecast till 2023:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Overview

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

Chapter 5. Market Factor Analysis

TOC CONTINUED…

Browse Complete 100 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at https://www.marketresearchfuture.com/reports/generic-injectables-market-7512

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India